Skip to main content

Table 1 The patients’ characteristics

From: The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer

Age (years)
 Median (range) 63 (27–86)
Gender
 Male 57
 Female 42
Location of primary tumor
 Colon 57
 Rectum 42
Histological type
 Well, moderately 78
 Poorly, mucinous 12
 Unknown 9
Detection of unresectable tumor
 Synchronous 59
 Metachronous 40
The number of organs affected by metastasis
 One organ 54
 Multiple organs 45
First-line chemotherapy regimen
 FOLFOX 65
 CapeOX 21
 FOLFIRI 9
 SOX 4
Molecular targeted therapy
 Bevacizumab 50
 Cetuximab 15
 Panitumumab 4
 None 30
The pretreatment C-reactive protein level
 Median (range) 0.32 (0.02–13.46)
The pretreatment albumin level
 Median (range) 3.9 (2.4–4.7)
The pretreatment CRP/ALB ratio
 Median (range) 0.084 (0.004–5.608)
The pretreatment NLR
 Median (range) 2.788 (0.580–16.306)
mGPS
 0 69
 1 21
 2 9
  1. FOLFOX 5-fluorouracil + leucovorin + oxaliplatin, CapeOX capecitabine + oxaliplatin, FOLFIRI 5-fluorouracil + leucovorin + irinotecan, SOX S-1 + oxaliplatin, CRP/ALB ratio C-reactive protein to albumin ratio, NLR neutriphil to lymphocyte ratio, mGPS modified Glasgow prognostic score